Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
O43151
UPID:
TET3_HUMAN
Alternative names:
-
Alternative UPACC:
O43151; A6NEI3; J3KNF3; K9JJH7; Q86Z24; Q8TBM9
Background:
Methylcytosine dioxygenase TET3 plays a pivotal role in epigenetic modifications, catalyzing the conversion of 5-methylcytosine into derivatives crucial for chromatin reprogramming post-fertilization. It selectively binds to gene promoters, regulating developmental gene expression and is instrumental in DNA demethylation, particularly in the paternal pronucleus of zygotes.
Therapeutic significance:
Given its involvement in Beck-Fahrner syndrome, characterized by a spectrum of developmental disorders, TET3's functional understanding could pave the way for innovative therapeutic approaches targeting genetic and epigenetic mechanisms underlying such conditions.